SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis
Version of Record online: 31 MAY 2012
Copyright © 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
EMBO Molecular Medicine
Volume 4, Issue 8, pages 776–790, August 2012
How to Cite
Gao, M., Patel, R., Ahmad, I., Fleming, J., Edwards, J., McCracken, S., Sahadevan, K., Seywright, M., Norman, J., Sansom, O. and Leung, H. Y. (2012), SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis. EMBO Mol Med, 4: 776–790. doi: 10.1002/emmm.201100944
- Issue online: 3 AUG 2012
- Version of Record online: 31 MAY 2012
- Manuscript Accepted: 20 APR 2012
- Manuscript Revised: 6 APR 2012
- Manuscript Received: 10 SEP 2011
- Funded Access
Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.